PRLDPrelude Therapeutics IncorporatedHealthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $4.47 · now $4.47 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, PRLD has typically landed between $3.02 and $6.73 — a range of −32.4% to +50.6% from the issuance price $4.47.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

1,478 overlapping 1 month windows · 2020-09-252026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.756.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($4.47) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where PRLD has typically landed a month from the 2026-09-16 close of $4.47 — the range is history, not a prediction.

$3.02worst · -32.4%$6.73best · +50.6%
  • now $4.47 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $4.32 (-3.3%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $3.55$5.1
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $3.02$6.73
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 1,478 windows spanning 2020-09-25 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2024-09-10−64.7%−64.9%+0.0%
2024-09-04−63.5%−63.5%+3.9%
2024-08-26−62.0%−62.0%+0.0%
3 best
2025-12-02+102.2%+0.0%+117.8%
2023-10-31+95.9%+0.0%+113.0%
2025-12-05+93.8%+0.0%+101.4%

1,478 overlapping windows · 2020-09-252026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~6 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
17%
−16.1%
n=6
Feb
33%
+3.8%
n=6
Mar
67%
−2.7%
n=6
Apr
50%
+5.5%
n=6
May
17%
−11.5%
n=6
Jun
33%
+2.3%
n=6
Jul
33%
+7.4%
n=6
Aug
67%
+18.2%
n=6
Sep
17%
−16.5%
n=6
Oct
50%
−17.1%
n=6
Nov
50%
+19.4%
n=6
Dec
67%
+23.2%
n=6

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$7$12026-04-21: 6 insider purchases, $35.0M — BAKER BROS. ADVISORS LP, ORBIMED ADVISORS LLC, Bonita David P …2026-04: 6 open-market purchases, $35.0M↑ buys↓ salesdirector BAKER BROS. ADVISORS LP — Purchase on 2026-04-21, filed 1 day after the tradedirector ORBIMED ADVISORS LLC — Purchase on 2026-04-21, filed 2 days after the tradedirector Bonita David P — Purchase on 2026-04-21, filed 2 days after the tradedirector ORBIMED ADVISORS LLC — Purchase on 2026-04-21, filed 2 days after the tradedirector Bonita David P — Purchase on 2026-04-21, filed 2 days after the tradedirector BAKER BROS. ADVISORS LP — Purchase on 2026-04-21, filed 1 day after the trade
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2026-04-21BAKER BROS. ADVISORS LPdirectorPurchase2,137,651 @ $4.44$9.5M+11.9% of holding−7.9%not yet — horizon still open20,105,994Form 4 · filed 1 day after the trade
2026-04-21ORBIMED ADVISORS LLCdirectorPurchase1,689,189 @ $4.44$7.5M+16.7% of holding−7.9%not yet — horizon still open11,808,945Form 4 · filed 2 days after the trade
2026-04-21Bonita David PdirectorPurchase1,689,189 @ $4.44$7.5M+16.7% of holding−7.9%not yet — horizon still open11,808,945Form 4 · filed 2 days after the trade
2026-04-21ORBIMED ADVISORS LLCdirectorPurchase1,126,126 @ $4.44$5.0Mownership Δ n/a−7.9%not yet — horizon still open1,126,126Form 4 · filed 2 days after the trade
2026-04-21Bonita David PdirectorPurchase1,126,126 @ $4.44$5.0Mownership Δ n/a−7.9%not yet — horizon still open1,126,126Form 4 · filed 2 days after the trade
2026-04-21BAKER BROS. ADVISORS LPdirectorPurchase114,601 @ $4.44$509K+7.3% of holding−7.9%not yet — horizon still open1,678,273Form 4 · filed 1 day after the trade
2025-03-25Vaddi KrishnadirectorPurchase675,000 @ $0.69$467K+51.0% of holding+28.9%+52.7%1,999,296Form 4 · filed 2 days after the trade
2025-03-25Combs AndrewofficerPurchase100,000 @ $0.69$69K+26.3% of holding+28.9%+52.7%480,123Form 4 · filed 2 days after the trade
2025-03-21Vaddi KrishnadirectorPurchase15,000 @ $0.73$11K+1.1% of holding+38.6%+23.2%1,324,296Form 4 · filed 3 days after the trade
2025-03-20Vaddi KrishnadirectorPurchase5,416 @ $0.73$4K+0.4% of holding+17.3%+15.3%1,309,296Form 4 · filed 4 days after the trade
2025-03-17Vaddi KrishnadirectorPurchase9,106 @ $0.75$7K+0.7% of holding+4.6%+36.6%1,303,880Form 4 · filed 1 day after the trade
2025-03-14Vaddi KrishnadirectorPurchase29,999 @ $0.75$23K+2.4% of holding−2.9%+30.9%1,294,774Form 4 · filed 4 days after the trade
2025-03-13Vaddi KrishnadirectorPurchase50,000 @ $0.72$36K+4.1% of holding+3.1%+39.9%1,264,775Form 4 · filed 1 day after the trade
2025-03-12Vaddi KrishnadirectorPurchase47,500 @ $0.71$34K+4.1% of holding−2.0%+55.4%1,214,775Form 4 · filed 2 days after the trade
2024-12-31Vaddi KrishnadirectorPurchase5,000 @ $1.21$6K+3.6% of holding−14.6%−43.0%142,553Form 4 · filed 3 days after the trade
2024-12-30Vaddi KrishnadirectorPurchase10,000 @ $1.20$12K+7.8% of holding−11.4%−41.3%137,553Form 4 · filed 3 days after the trade
2024-12-23Combs AndrewofficerPurchase60,000 @ $1.37$82K+18.9% of holding−9.7%−40.7%377,623Form 4 · filed 3 days after the trade
2024-12-20Combs AndrewofficerPurchase3,075 @ $1.15$4K+1.0% of holding−9.0%−38.0%317,623Form 4 · filed 6 days after the trade
2024-12-19Lim Bryant DavidofficerPurchase25,000 @ $0.91$23K+1041.7% of holding+24.0%−8.3%27,400Form 4 · filed 1 day after the trade
2024-12-19Vaddi KrishnadirectorPurchase6,888 @ $0.89$6K+5.7% of holding+24.0%−8.3%127,553Form 4 · filed 1 day after the trade
2024-12-18Vaddi KrishnadirectorPurchase100,000 @ $0.93$93K+9.4% of holding+25.3%−7.8%1,167,275Form 4 · filed 2 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

49 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-06-09Babler MartindirectorAward / grant38,00038,000Form 4
2026-06-09Bonita David PdirectorAward / grant38,00038,000Form 4
2026-06-09BAKER BROS. ADVISORS LPdirectorAward / grant38,00038,000Form 4
2026-06-09Dorton KatinadirectorAward / grant38,00038,000Form 4
2026-06-09FRIEDMAN PAUL AdirectorAward / grant38,00038,000Form 4
2026-06-09Sandor VictordirectorAward / grant38,00038,000Form 4
2026-05-01Morris Charles QofficerAward / grant450,000450,000Form 4
2026-04-27RA CAPITAL MANAGEMENT, L.P.directorOther acquisition1,407,0006,475,882Form 4
2026-04-27RA CAPITAL MANAGEMENT, L.P.directorOther acquisition1,407,0006,475,882Form 4
2026-04-27RA CAPITAL MANAGEMENT, L.P.directorOther acquisition1,407,0001,407,000Form 4
2026-04-27RA CAPITAL MANAGEMENT, L.P.directorOther acquisition1,407,0006,475,882Form 4
2026-04-27RA CAPITAL MANAGEMENT, L.P.directorOther acquisition1,407,0001,407,000Form 4
2026-04-27RA CAPITAL MANAGEMENT, L.P.directorOther acquisition1,407,0001,407,000Form 4
2026-04-27RA CAPITAL MANAGEMENT, L.P.directorOther acquisition1,407,0006,475,882Form 4
2026-04-27RA CAPITAL MANAGEMENT, L.P.directorOther acquisition1,407,0001,407,000Form 4
2026-04-27RA CAPITAL MANAGEMENT, L.P.directorOther acquisition1,407,0006,475,882Form 4
2026-04-27RA CAPITAL MANAGEMENT, L.P.directorOther acquisition1,407,0001,407,000Form 4
2026-02-04Vaddi KrishnadirectorAward / grant837,000837,000Form 4
2026-02-04Lim Bryant DavidofficerAward / grant275,000275,000Form 4
2026-02-04Scherle PeggyofficerAward / grant230,000230,000Form 4
2026-02-04Combs AndrewofficerAward / grant230,000230,000Form 4
2025-11-05Sandor VictordirectorAward / grant121,285121,285Form 4
2025-10-17Dorton KatinadirectorAward / grant76,00076,000Form 4
2025-10-04Huang JanedirectorWithheld for tax3,35586,917Form 4
2025-10-04Huang JanedirectorOption exercise9,37518,750Form 4
2025-10-04Huang JanedirectorOption exercise9,37590,272Form 4
2025-10-04Huang JanedirectorOption exercise9,37590,272Form 4
2025-07-04Huang JanedirectorWithheld for tax3,35580,897Form 4
2025-07-04Huang JanedirectorOption exercise9,37528,125Form 4
2025-07-04Huang JanedirectorOption exercise9,37584,252Form 4
2025-07-04Huang JanedirectorOption exercise9,37584,252Form 4
2025-06-12BAKER BROS. ADVISORS LPdirectorAward / grant76,00076,000Form 4
2025-06-12Bonita David PdirectorAward / grant38,00038,000Form 4
2025-06-12Dier MardidirectorAward / grant38,00038,000Form 4
2025-06-12Sandor VictordirectorAward / grant38,00038,000Form 4
2025-06-12Babler MartindirectorAward / grant38,00038,000Form 4
2025-06-12FRIEDMAN PAUL AdirectorAward / grant38,00038,000Form 4
2025-04-04Huang JanedirectorWithheld for tax3,35574,877Form 4
2025-04-04Huang JanedirectorOption exercise9,37537,500Form 4
2025-04-04Huang JanedirectorOption exercise9,37578,232Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.